PA-EXONE
22.9.2020 14:02:08 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today debuted a concept rendering of the InnoventPro, a preview of the world’s most advanced entry-level binder jetting system for printing metals, ceramics and composites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005243/en/
The InnoventPro will be a major upgrade of the Innovent+, the world’s best-selling metal binder jetting system since 2016. The InnoventPro will offer two new build sizes, a 3-liter and a 5-liter, with print speeds topping 700 cc/hour. The updated system is aimed at academics, researchers, and a full spectrum of manufacturers, from machine and MIM shops to high-volume producers, who want to produce metal parts quickly, affordably and sustainably.
“Customers around the world already love the Innovent+, and based on their feedback, we’re going to give them an updated entry-level system that’s bigger, faster and smarter than ever,” said John Hartner, ExOne CEO.
Siemens Digital Industries will serve as an Industry 4.0 collaboration partner on the production version of the machine, to be unveiled in the second half of 2021. An incentive program for the InnoventPro will be offered to customers who buy an Innovent+ prior to commercial availability of the new system. Learn more at www.exone.com/InnoventPro
Raising the bar in binder jetting
Binder jetting is a groundbreaking 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.
Binder jetting is a sustainable method of manufacturing that reduces material waste to less than 5%, saves energy by consolidating many assembled parts and processes into one, and can deliver end-use products that are 30-40% lighter — for more efficient cars, planes and military equipment.
Importantly, the new InnoventPro will feature the same recirculating printhead modules used on the X1 25Pro® and X1 160Pro™ metal 3D printers, allowing users to easily scale up from R&D to high-volume production.
The recirculating printhead also enables ExOne’s pioneering move to offer particulate binders as an option on a commercial binder jetting system. The ExOne research team has been 3D printing a variety of nanoparticles suspended in its binders for years.
All-New Class of NanoFuse Binders
First patented in 2018 , with related patents pending worldwide, ExOne’s “inkjet-printable nanoparticle suspensions” are slated for commercial deployment in the InnoventPro. This all-new class of ExOne NanoFuse binders advances the field of binder jet 3D printing in critical ways.
Because nanoparticles fill in the interstices between powder bed particles and can bond at lower temperatures, they enable stronger green parts. In turn, this enables 3D printing of larger parts and finer features, delivering sharper corners and edges. These new binders can also improve the resolution and sinterability of high-demand metals, such as copper and aluminum.
Rick Lucas, ExOne CTO and VP, New Markets, said the InnoventPro and new NanoFuse binders show how ExOne continues to lead the way in commercial development of binder jetting.
“Just as the current Innovent+ served as the proving ground for our patented Triple ACT system, which now delivers industry-leading quality in metal binder jetting, the InnoventPro will offer groundbreaking new features in a commercial system,” Lucas said. “Our patented approach to 3D printing particulate inks in a print bed is opening new doors in binder jetting.”
ExOne’s patented Triple ACT is a critical advanced compaction technology that, depending on material, delivers industry-leading final part density of 97+%, dimensional tolerances in the range of <1%-2.5%, and high consistency, with part variation of just 0.3% across the print bed.
Triple ACT has been so effective that it has also sped up ExOne’s qualification of new materials. ExOne binder jet systems now process more than 20 metal, ceramic and composite materials , with single-alloy metals making up more than half of those offerings. NanoFuse binders are expected to expand that material range and improve sintering dynamics.
A webinar about NanoFuse will be held at 9 a.m. on Wednesday, Nov. 4. Details are available at https://tinyurl.com/NanoFuseWebinar .
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005243/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
